A tough nut to crackBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7485.0-h (Published 27 January 2005) Cite this as: BMJ 2005;330:0-h
- Kamran Abbasi, acting editor ()
“The drug industry considers the BMJ a tough nut to crack,” an insider recently told us. Publishing a “favourable” research paper is far trickier in the BMJ than other journals, he said, but when a paper is published it's worth £200m to the company. Some of that revenue inevitably finds its way into the “swimming pool” funds of highly paid doctors who trot the globe's conference venues putting a positive spin on company products. “You're just anti-industry,” complains one of our marketing team, pointing an accusing finger at the BMJ's editors. We're not anti-industry, of course, we just like to think we're a tough nut to crack—and that's official.
But this week brings good news about drugs and interventions for women. Gianni Bonadonna and colleagues complete a 30 year follow up of randomised studies of adjuvant treatment with cyclophosphomide, methotrexate, and fluorouracil in patients with operable breast cancer and find longlasting benefits with minimal detrimental effects (p 217). A ten year cohort study of mammographic screening in Copenhagen reveals a reduction in breast cancer mortality of 25% (p 220). A nested case-control study by Lucie Blais and others shows that use of inhaled corticosteroids during pregnancy probably does not increase the risk of pregnancy induced hypertension or pre-eclampsia, although a bigger study still would give a more precise estimate of risk (p 230).
Two more studies focus on women's health and evaluate the use of chaperones for intimate examinations. Joe Rosenthal's team survey almost 2000 general practitioners across England and find a substantial increase in the use of chaperones by male doctors over the past two decades, although the use of chaperones by female doctors remains low (p 234). Record keeping is poor, and availability of chaperones and time constraints remain important barriers. The second survey of general practitioners, this time across Norfolk, concludes that although offering chaperones has increased, the use of chaperones has shown less change (p 236).
Elsewhere, this issue quivers to the sound of nuts being cracked. “The BMJ's rigorously exercised editorial independence is well shown,” begins James Johnson as he and others respond forcefully to our editorial on the General Medical Council (p 252). Yoram Blacher, president of the Israeli Medical Association, hits back at Derek Summerfield for his “much debated” article on health in Palestine (p 254). David Katz explains why the Israeli situation is not analogous to the apartheid regime.
Solving the puzzle of aid reaching victims of the tsunami is tough too, but public health specialists from the United States and the World Health Organization explain why much of the aid promised immediately after disasters does not reach those affected (p 247, p 250). Of the $1bn pledged after the Bam earthquake in Iran, for example, only $116m has been delivered in a year. Will compassion produce better results this time?
To receive Editor's choice by email each week subscribe via our website:bmj.com/cgi/customalert